Ga-68-PSMA PET is advantageous over other imaging techniques to detect prostate cancer recurrence, especially in patients with low PSA levels, but the reported detection rate of metastatic sites in patients with biochemical recurrence after radical prostatectomy in a PSA-range of 0.5–1.0 ng/ml does not surpass 73% [5]. The gene discussed is FOLH1; the disease is prostate carcinoma.